Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 276-282

  Asami, Kazuhiro ^a   Okuma, Tomohisa ^a   Hirashima, Tomonori ^b   Kawahara, Masaaki ^c   Atagi, Shinji ^a   Kawaguchi, Tomoya ^a   Okishio, Kyoichi ^a   Omachi, Naoki ^a   Takeuchi, Naoko ^a  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c Otemae Hospital   (Japan)

Author keywords

Beyond PD; EGFR mutation; Gefitinib; Non small cell lung cancer; Secondary resistance

Indexed keywords

ARGININE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LYSINE; PLATINUM DERIVATIVE;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTICENTER STUDY; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT DURATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84873189254     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.022     Document Type: Article

References (26)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
3. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75:191-202.
4. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55:5536-5539.
5. Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23:3227-3234.
6. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
8. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
9. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23:2513-2520.
10. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
13. Choong N.W., Dietrich S., Seiwert T.Y., Tretiakova M.S., Nallasura V., Davies G.C., et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nat Clin Pract Oncol 2006, 3:50-57. [quiz 51 p following 57].
14. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
15. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
16. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
17. Yano S., Wang W., Li Q., Matsumoto K., Sakurama H., Nakamura T., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008, 68:9479-9487.
18. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002, 20:4292-4302.
19. Asami K., Kawahara M., Atagi S., Kawaguchi T., Okishio K. Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. Lung Cancer 2011, 73:211-216.
20. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., et al. 2011 Focused Update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
21. Riely G.J., Kris M.G., Zhao B., Akhurst T., Milton D.T., Moore E., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
22. Oxnard G.R., Arcila M.E., Sima C.S., Riely G.J., Chmielecki J., Kris M.G., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
23. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
24. Suda K., Onozato R., Yatabe Y., Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival?. J Thorac Oncol 2009, 4:1-4.
25. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
26. Comis R.L. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005, 10:467-470.